[EN] COMPOUNDS AND METHODS FOR INHIBITION OF BAX-MEDIATED CELL DEATH [FR] COMPOSÉS ET PROCÉDÉS PERMETTANT L'INHIBITION DE LA MORT CELLULAIRE MÉDIÉE PAR BAX
The invention relates to new pteridines which are suitable for treating respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system and cancers. This invention also relates to pharmaceutical compositions containing these compounds.
PHENYLAMINO ISOTHIAZOLE CARBOXAMIDINES AS MEK INHIBITORS
申请人:Abdellaoui Hassan
公开号:US20080306063A1
公开(公告)日:2008-12-11
The invention concerns compounds which inhibit MEK and which have activity as anti-neoplastic agents. These compounds include N-substituted-3-hydroxy-5-arylamino-isothiazole-4-carboxamidines. Also included are the tautomeric isothiazol-3(2H)-ones.
COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION
申请人:Brown Matthew
公开号:US20080312270A1
公开(公告)日:2008-12-18
Compounds, compositions and methods that are useful in the treatment of inflammatory and immune-related diseases and conditions are provided herein. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.
METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT
申请人:Errico Joseph P.
公开号:US20110301193A1
公开(公告)日:2011-12-08
Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR.
The invention relates to naphthalene derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.